← Browse by Condition
Medical Condition

gastric adenocarcinoma

Total Trials
10
Recruiting Now
10
Trial Phases
Phase 3, Phase 1, Phase 2

ClinicalMetric tracks all active clinical trials for gastric adenocarcinoma sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — gastric adenocarcinoma Clinical Trials

How many clinical trials are currently recruiting for gastric adenocarcinoma?
ClinicalMetric currently tracks 10 actively recruiting clinical trials for gastric adenocarcinoma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 10. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for gastric adenocarcinoma?
gastric adenocarcinoma research spans Phase 1 (2 trials), Phase 2 (5 trials), Phase 3 (3 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a gastric adenocarcinoma clinical trial?
Eligibility criteria for gastric adenocarcinoma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
2
Phase 2
5
Phase 3
3
Top Sponsors
Suzhou Immunofoco Biotechnology Co., Ltd 1 trial
Imperial College London 1 trial
Dispatch Biotherapeutics 1 trial
Normunity AccelCo, Inc. 1 trial
Memorial Sloan Kettering Cancer Center 1 trial

Recruiting Clinical Trials

NCT07103668 Phase 3
Recruiting
A Phase III Randomized Study in CLDN18.2-positive Unresectable Locally Advanced Gastric Cancer Patients
Enrollment
150 pts
Location
China
Sponsor
Suzhou Immunofoco Biotechnolog...
View Trial →
NCT06289374
Recruiting
Longitudinal Assessment of Biomarkers After Oesophagogastric Cancer Surgery
Enrollment
100 pts
Location
United Kingdom
Sponsor
Imperial College London
View Trial →
NCT07544589 Phase 1
Recruiting
A Phase 1 Study Evaluating DISP-10 in Participants With Advanced Gastrointestinal Cancers
Enrollment
66 pts
Location
United States
Sponsor
Dispatch Biotherapeutics
View Trial →
NCT07182149 Phase 1
Recruiting
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
Enrollment
150 pts
Location
United States
Sponsor
Normunity AccelCo, Inc.
View Trial →
NCT06123338 Phase 2
Recruiting
A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer
Enrollment
49 pts
Location
United States
Sponsor
Memorial Sloan Kettering Cance...
View Trial →
NCT04114136 Phase 2
Recruiting
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
Enrollment
72 pts
Location
United States
Sponsor
Dan Zandberg
View Trial →
NCT07152405 Phase 3
Recruiting
A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-positive Locally Advanced or Metastatic Gastric or Gastro-esophageal Junction Adenocarcinoma
Enrollment
490 pts
Location
China
Sponsor
Sichuan Baili Pharmaceutical C...
View Trial →
NCT07007182 Phase 2
Recruiting
Conversion Therapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric Cancer
Enrollment
54 pts
Location
China
Sponsor
Jinbo Yue
View Trial →
NCT07263386 Phase 2
Recruiting
A Phase II, Multicenter, Randomized, Controlled Clinical Study Comparing the Efficacy and Safety of Sintilimab Plus SOX Versus SOX Alone as Adjuvant Therapy for PD-L1-Positive, Stage pN3 Gastric Cancer
Enrollment
460 pts
Location
China
Sponsor
The First Affiliated Hospital ...
View Trial →
NCT06028737 Phase 2, Phase 3
Recruiting
Total Neoadjuvant FLOT Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer
Enrollment
150 pts
Location
Lithuania, Ukraine
Sponsor
Ukrainian Society of Clinical ...
View Trial →

Related Conditions

esophageal adenocarcinoma (3) hnscc (2) nsclc (2) gastroesophageal junction adenocarcinoma (2) oesophageal adenocarcinoma (1) colorectal cancer (1) gastroesophageal adenocarcinoma (1) escc (1) gej adenocarcinoma (1) ovarian cancer (1) cervical cancer (1) endometrial cancer (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology